TIGAR Antibody (F-5): sc-377065

TIGAR Antibody (F-5) is a mouse monoclonal IgG2a antibody that detects TIGAR (TP53-induced glycolysis and apoptosis regulator) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TIGAR is a 270 amino acid protein that plays a crucial role in cellular metabolism and stress response, being induced by the p53 tumor suppressor pathway to protect cells against oxidative stress. One of the key functions of TIGAR is its ability to lower intracellular levels of fructose-2,6-bisphosphate, which is a potent activator of glycolysis. By inhibiting glycolysis, TIGAR redirects metabolic flux towards the pentose phosphate pathway, thereby reducing the concentration of reactive oxygen species within the cell. This function is particularly important as excessive reactive oxygen species can cause DNA damage and trigger apoptosis, highlighting TIGAR′s protective role in maintaining cellular integrity under stress conditions. Anti-TIGAR antibody (F-5) is an essential tool for researchers studying the mechanisms of cellular metabolism and the protective responses mediated by the p53 pathway.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TIGAR Antibody (F-5) References:

1. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.  |  Lui, VW., et al. 2011. Oncogene. 30: 1127-34. PMID: 21057531
2. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.  |  Wanka, C., et al. 2012. J Biol Chem. 287: 33436-46. PMID: 22887998
3. TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells.  |  Li, B., et al. 2019. Acta Pharmacol Sin. 40: 111-121. PMID: 29769743
4. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.  |  Chu, J., et al. 2020. Theranostics. 10: 3488-3502. PMID: 32206103
5. The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.  |  Agca, CA., et al. 2020. Chem Biodivers. 17: e2000441. PMID: 32639659
6. Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.  |  Song, Y., et al. 2021. Nucl Med Commun. 42: 528-534. PMID: 33481504
7. The Expression of TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Can Be Controlled by the Antioxidant Orchestrator NRF2 in Human Carcinoma Cells.  |  Simon-Molas, H., et al. 2022. Int J Mol Sci. 23: PMID: 35163828
8. The inhibition of TRIM35-mediated TIGAR ubiquitination enhances mitochondrial fusion and alleviates renal ischemia-reperfusion injury.  |  Du, Y., et al. 2022. Int J Biol Macromol. 209: 725-736. PMID: 35421414
9. Ginsenoside Rg3 induces apoptosis and inhibits proliferation by down-regulating TIGAR in rats with gastric precancerous lesions.  |  Lv, S., et al. 2022. BMC Complement Med Ther. 22: 188. PMID: 35840932
10. Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinoma.  |  Yang, C., et al. 2022. Cancer Sci. 113: 4151-4164. PMID: 36114745

The preferred TIGAR antibody is TIGAR Antibody (E-2): sc-166290.